Table 2.

Treatment Coverage of Eligible Populations per Study Community, as Assessed from a Population Census

	Mean (95% CI)
	MDA (N = 16)				Targeted (N = 16)
Characteristic	First Year		Second Year		First Year		Second Year
All ages
Total, no.	244	(174–315)	252	(166–338)	195	(128–262)	228	(155–300)
Eligible for treatment, no.	244	(174–315)	252	(166–338)	2	(1–4)	10	(4–15)
Received treatment, no.a	216	(156–275)	216	(145–286)	2	(1–4)	9	(4–14)
Coverage (eligible), %	89%	(87–91%)	86%	(84–89%)	100%	(>99–100%)	98%	(96–100%)
Coverage (total), %	89%	(87–91%)	86%	(84–89%)	1%	(>0–2%)	3%	(2–5%)
0–5 years
Total, no.	49	(33–66)	49	(28–70)	38	(22–53)	40	(27–52)
Eligible for treatment, no.	49	(33–66)	49	(28–70)	2	(1–4)	10	(4–15)
Received treatment, no.a	45	(30–61)	44	(26–62)	2	(1–4)	9	(4–14)
Coverage (eligible), %	92%	(89–96%)	91%	(87–95%)	100%	(>99–100%)	98%	(96–100%)
Coverage (total), %	92%	(89–96%)	91%	(87–95%)	7%	(2–12%)	17%	(7–27%)
8–12 years
Total, no.	36	(26–46)	38	(25–50)	30	(20–40)	34	(23–46)
Eligible for treatment, no.	36	(26–46)	38	(25–50)	0	(0–0)	0	(0–0)
Received treatment, no.a	33	(24–43)	33	(22–44)	0	(0–0)	0	(0–0)
Coverage (eligible), %	93%	(90–96%)	88%	(83–92%)	0%	(0–0%)	0%	(0–0%)
Coverage (total), %	93%	(90–96%)	88%	(83–92%)	0%	(0–0%)	0%	(0–0%)

No one in the 16 delayed treatment villages was eligible for or received treatment during the study. The mean total population in the delayed treatment arm was 173 (95% CI: 128–217) for the first year and 186 (95% CI: 141–231) for the second year; the mean population of 0–5 year-olds was 31 (95% CI: 22–40) for the first year and 34 (95% CI: 25–43) for the second year; the mean population of 8–12 year-olds was 24 (95% CI: 17–31) for the first year and 25 (95% CI: 18–32) for the second year.

Abbreviations: CI, confidence interval; MDA, mass drug administration.

^a Indicates a single dose of azithromycin for the MDA group and all 3 treatments for the targeted group.